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Background:  Diabetic peripheral polyneuropathy (DPP) is one of the common complications of diabetes mellitus (DM) and 
can lead to foot ulcers or amputation. The pathophysiology of DPP includes several factors such as metabolic, vascular, autoim-
mune, oxidative stress and neurohormonal growth-factor deficiency and recent studies have suggested the use of serum gamma-
glutamyl transferase (GGT) as an early marker of oxidative stress. Therefore, we investigated whether serum GGT may be useful 
in predicting DPP. 
Methods:  We assessed 90 patients with type 2 DM who were evaluated for the presence of DPP using clnical neurologic exami-
nations including nerve conduction velocity studies. We evaluated the association between serum GGT and the presence of DPP. 
Results:  The prevalence of DPP was 40% (36 cases) according to clinical neurological examinations. The serum GGT concen-
tration was significantly elevated in type 2 diabetic patients with DPP compared to patients without DPP (P < 0.01). There were 
other factors significantly associated with DPP including smoking (P = 0.019), retinopathy (P = 0.014), blood pressure (P < 0.05), 
aspartate aminotransferase (P = 0.022), C-reactive protein (P = 0.036) and urine microalbumin/creatinine ratio (P = 0.004). Se-
rum GGT was independently related with DPP according to multiple logistic analysis (P < 0.01). 
Conclusion:  This study shows that increased levels of serum GGT may have important clinical implications in the presence of 
DPP in patients with type 2 diabetes.
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INTRODUCTION
Diabetes mellitus (DM) is a metabolic disorder, of which the 
number of patients is rapidly increasing worldwide due to sev-
eral conditions such as aging, westernization, and increasing 
prevalence of obesity and physical inactivity every year, and par-
ticularly, it is one of the major treatment-requiring diseases 
nowadays [1]. Diabetic peripheral polyneuropathy (DPP), one 
of the common complications of DM, predisposes the patient 
to foot ulcers or amputation [2]. DPP is associated with vari-
ous symptoms including paresthesia, numbness, pain, muscle 
weakness, and loss of reflexes. The prevalence of DPP is under-
reported due to the lack of consistent diagnostic standards [3, 
4]. Several objective methods have been used for screening and 
early detection of peripheral polyneuropathy including the 
Michigan neuropathy screening instrument (MNSI) [5], vibra-
tion perception threshold test [6], tactile tests performed with 
monofilament [7], quantitative pressure threshold test [8], and 
nerve conduction velocity (NCV) examinations [2,3]. 
  The pathophysiology of diabetic neuropathy includes sever-
al factors such as metabolic, vascular, autoimmune, oxidative 
stress, and neurohormonal growth-factor deficiency [3]. Re-
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cent studies have reported that oxidative stress may apparent 
in pathology associated with metabolic syndrome and neuro-
degenerative disease and suggested that serum gamma-glu-
tamyl transferase (GGT) may be an early marker of oxidative 
stress [9,10]. Therefore, we investigated the relationships be-
tween DPP and serum GGT as a marker of oxidative stress 
which may be one of mechanisms of polyneuropathy by analy-
sis of key factors for development of DPP in type 2 diabetic 
patients.
METHODS
 
Study population
The study was conducted under voluntary informed consent. 
Ninety patients with type 2 DM who underwent work-ups for 
peripheral polyneuropathy including NCV studies in Daegu 
Medical Center from January 2009 to November 2009. Patients 
were excluded from this study if they had a history of chronic 
alcohol consumption, hepatobiliary disorders, or any other 
acute disease. Those patients with blood levels greater than 
three times that of normal aspartate aminotransferase (AST) 
or alanine aminotransferase (ALT) were excluded. Patients 
who had neuropathy other than diabetic neuropathy, or who 
had problems in the evaluation of DPP due to other reasons 
were also excluded.
Study design and assessments
A detailed questionnaire was completed for each of the 90 par-
ticipating patients. Information obtained included age, gender, 
smoking history, history of alcohol consumption, duration of 
DM, history of hypertension or cardiovascular diseases, and 
symptoms related to peripheral neuropathy. In addition, age, 
height, waist circumference, neurologic physical examination, 
fasting blood glucose (FBG), 2 hours postprandial blood glu-
cose (2PPBG), C-peptide, and insulin levels were obtained. 
Baseline laboratory data including serum GGT, AST, ALT, gly-
cosylated hemoglobin (HbA1c), creatinine, C-reactive protein 
(CRP) and lipid profiles were analyzed using the ARCHITECT 
c8000 (Toshiba, Tokyo, Japan). 
  We evaluated symptoms and the degree of DPP using the 
MNSI [5]. Physical examinations were performed to assess loss 
or weakening of the knee and ankle jerk reflexes, weakened 
perception to vibration, and a monofilament was used to per-
form tactile tests of the foot including big toes, the instep, and 
the sole [11]. 
  NCV examinations were performed according to the stan-
dard method using the Synergy
® instrument (Oxford Mede-
lec, Wiesbaden, Germany) at 20 to 25°C room temperature. 
The presence of polyneuropathy was documented by evaluat-
ing the latencies, amplitudes, and conduction velocities for mo-
tor nerves in both median, ulna, posterior tibial, and peroneal 
Table 1. Baseline clinical and laboratory characteristics of the 
subjects (n = 90)
Parameter Median (Min - Max) Mean ± SD
Age, yr 59 (33-84) 59 ± 12
Height, cm 158.5 (140.0-177.0) 159.3 ± 8.4
Weight, kg 61.0 (44.0-105.0) 62.1 ± 12.5
BMI, kg/m
2 23.9 (16.6-42.7) 24.4 ± 4.2
Waist, cm 88.0 (69.0-121.0) 87.8 ± 9.8
Waist/Hip ratio 0.9 (0.8-1.1) 0.9 ± 0.0
DM duration, yr 7.0 (0-30.0) 8.7 ± 6.9
Smoking, n (%) 32 (35.6)
Hypertension Hx, n (%) 43 (47.8)
CVA Hx, n (%) 5 (5.6)
Retinopathy, n (%) 56 (62.2)
SBP, mm Hg 120.0 (100.0-165.0) 125.4 ± 12.3
DBP, mm Hg 80.0 (50.0-110.0) 78.0 ± 8.5
Hemoglobin, g/dL 13.3 (8.8-18) 13.1 ± 1.8
HbA1c, % 7.2 (5.0-15.6) 8.0 ± 2.1
FBG, mmol/L 7.6 (4.7-19.0) 8.2 ± 2.5
2PPBG, mmol/L 12.1 (6.3-30.2) 12.9 ± 4.9
C-peptide, mmol/L 1.0 (0.1-9.6) 1.4 ± 1.3
Total cholesterol, mmol/L 4.8 (2.6-13.0) 4.8 ± 1.4
Triglyceride, mmol/L 1.5 (0.5-4.5) 1.9 ± 1.0
HDL-C, mmol/L 1.3 (0.5-10.9) 1.5 ± 1.1
GGT, IU/L 25.5 (7.0-201.0) 42.4 ± 39.6
AST, IU/L 23.0 (9.0-118.0) 27.7 ± 17.0
ALT, IU/L 21.5 (6.0-103.0) 26.2 ± 1.8
Urine ACR, µg/mg 0.5 (0.0-34.8) 2.7 ± 6.1
BUN, mg/dL 15.2 (6.7-118.8) 17.4 ± 12.7
Creatinine, mg/dL 1.0 (0.6-3.1) 1.1 ± 0.4
CRP, mg/dL 0.1 (0.0-18.8) 1.1 ± 3.4
SD, standard deviation; BMI, body mass index; DM, diabetes melli-
tus; CVA, cerebrovascular accident; SBP, systolic blood pressure; DBP, 
diastolic blood pressure; HbA1c, glycosylated hemoglobin; FBG, 
fasting blood glucose; 2PPBG, 2 hours postprandial blood glucose; 
HDL-C, high density lipoprotein cholesterol; GGT, gamma-glutamyl 
transferase; AST, aspartate aminotransferase; ALT,  alanine amin-
otransferase; ACR, albumin-creatinine ratio; CRP, C-reactive protein.113
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nerves and the latencies, amplitudes for sensory nerves in both 
median, ulna, sural, and superficial peroneal nerves. 
  There are various methods used to diagnose DPP. In the pres-
ent study, DPP was defined as a positive NCV and a positive 
neurologic physical exam in patients with a clinical MNSI score 
≥ 3 and who also had accompanying neurologic symptoms such 
as paresthesia, numbness, pain, and tingling sensation and there 
was no apparent etiology of peripheral polyneuropathy besides 
diabetes [12]. Diabetic retinopathy was defined as cases with 
proliferative retinopathy or nonproliferative retinopathy ac-
cording to clinical ophthalmic examinations and the urinary 
albumin-creatinine ratio (ACR) was calculated to assess dia-
betic nephropathy [13].
Data analysis 
Statistical analysis was performed using SPSS version 15.0 (SPSS 
Inc., Chicago, IL, USA) and the baseline characteristics of par-
ticipants were presented as the mean ± standard deviation and n 
(%). Data were compared using an independent-sample Student 
t-test for continuous data, odds ratio and Chi-square test for 
categorical variables, and the Mann-Whitney U test for non-
parametric data with an irregular distribution. Multiple logistic 
regression analysis was performed to assess independent associ-
ations between key risk factors and the presence of DPP. A P 
value of less than 0.05 was considered statistically significant. 
RESULTS
Baseline characteristics 
There were 46 male patients and 44 females in this study and 
the mean age was 59 years. The average body mass index was 
24.4 (kg/m
2), the waist circumference was 87.8 cm, and the 
waist/hip ratio was 0.9. The duration of diabetes was on aver-
age 8.7 years. The laboratory data showed a mean HbA1c of 
8.0%, FBG of 8.2 mmol/L, 2PPBG of 12.9 mmol/L, C-peptide 
of 1.4 mmol/L, and a GGT of 42.4 IU/L. Other clinical and lab-
oratory characteristics are listed in Table 1.
Correlation between serum GGT and clinical 
characteristics in subjects
The analysis for correlation of serum GGT with clinical and 
biochemical characteristics of the subjects indicated that gen-
der, 2PPBG, and total cholesterol concentration were signifi-
cantly associated with serum GGT level with a positive corre-
lation (Table 2).
Clinical characteristics in type 2 diabetic patients according 
to the incidence of polyneuropathy
The number of patients with DPP was 36 (40%), while the num-
ber of patients without DPP was 54 (60%). The analysis of the 
clinical and biochemical characteristics between the two groups 
Table 2. Analysis for the correlation between serum GGT and clinical characteristics in subjects (n = 90)
Parameter No. Mean SD T/R P value
Sex Male
Female
46
44
50.7
33.6
48.2
25.6
2.113 0.038
HTN (-)
(+)
47
43
47.6
36.6
44.3
33.4
1.323 0.189
Retinopathy (-)
(+)
34
56
45.6
40.5
40.9
39.1
0.592 0.556
Age
a -0.027 0.803
Weight
a 0.001 0.991
DM duration
a -0.013 0.259
HbA1c
a 0.004 0.971
FBG
a 0.150 0.159
2PPBG
a 0.215 0.042
Total cholesterol
a 0.305 0.003
Triglyceride
a 0.195 0.066
GGT, gamma-glutamyl transferase; SD, standard deviation; T, t-test; R, correlation coefficient; HTN, hypertension; DM, diabetes mellitus; 
HbA1c, glycosylated hemoglobin; FBG, fasting blood glucose; 2PPBG, 2 hours postprandial blood glucose.
aCorrelation analysis.114
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showed no difference in age, gender, waist circumference, du-
ration of DM, history of hypertension, HbA1c, C-peptide, glu-
cose levels, cholesterol concentrations, or renal function (Tables 
3, 4). However, Tables 3, 4 do show that smoking history, dia-
betic retinopathy, systolic blood pressure (SBP), diastolic blood 
pressure (DBP), GGT, AST, CRP, and urine ACR in patients 
with DPP were significantly higher than those in patients with-
out DPP as 50% vs. 25.9%, 77.8% vs. 51.9%, 128.9 ± 11.8 mm 
Hg vs. 123.1 ± 12.1 mm Hg, 80.0 ± 10.4 mm Hg vs. 76.7 ± 6.7 
mm Hg, 66.1 ± 51.6 IU/L vs. 26.6 ± 15.4 IU/L, 34.1 ± 22.7 IU/L 
vs. 23.4 ± 10.0 IU/L, 1.3 ± 3.9 mg/dL vs. 0.9 ± 3.0 mg/dL, and 
4.6 ± 8.4 µg/mg vs. 1.5 ± 3.6 µg/mg. 
Multiple logistic regression model
To examine the independent associations between the key risk 
factors and the presence of DPP, we performed a multiple lo-
gistic regression analysis with the significant eight variables - 
smoking, retinopathy, SBP, DBP, serum GGT, AST, CRP, and 
urine ACR in univariate analysis. Only increased level of serum 
GGT remained independently associated with the presence of 
DPP, which carried a relative risk with an odds ratio of 1.1 (P <  0.01) (Table 5).
Table 3. Clinical characteristics in type 2 diabetic patients ac-
cording to the incidence of polyneuropathy (n = 90)
Parameter
Patients
without DPP 
(n=54)
Patients
with DPP 
(n=36)
P value
Age, yr 58 ± 12 62 ± 12 0.146
Sex, n (%)
   Male
   Female
24 (44.4)
30 (55.6)
22 (61.1)
14 (38.9)
0.121
DM duration, yr 7.7 ± 5.7 10.3 ± 8.1 0.236
Height, cm 158.1 ± 8.4 161.1 ± 8.4 0.106
Weight, kg 63.0 ± 11.4 60.6 ± 14.2 0.148
Waist circumference, cm 88.4 ± 9.3 86.9 ± 10.7 0.218
Waist-to-hip ratio 0.9 ± 0.0 0.9 ± 0.0 0.699
Hypertension Hx, n (%) 26 (48.1) 17 (47.2) 0.931
Smoking, n (%) 14 (25.9) 18 (50.0) 0.019
Retinopathy, n (%) 27 (51.9) 28 (77.8) 0.014
CVA Hx, n (%) 2 (3.7) 3 (8.3) 0.385
SBP, mm Hg 123.1 ± 12.1 128.9 ± 11.8 0.017
DBP, mm Hg 76.7 ± 6.7 80.0 ± 10.4 0.048
DPP, diabetic peripheral polyneuropathy; DM, diabetes mellitus; 
CVA, cerebrovascular accident; SBP, systolic blood pressure; DBP, di-
astolic blood pressure.
Table 4. Laboratory characteristics in type 2 diabetic patients 
according to the incidence of neuropathy (n = 90)
Parameter
Patients
without DPP 
(n=54)
Patients
with DPP 
(n=36)
P value
HbA1c, % 7.7 ± 1.7 8.4 ± 2.6 0.358
C-peptide, mmol/L 1.4 ± 1.4 1.3 ± 1.1 0.521
FBG, mmol/L 7.8 ± 2.0 8.7 ± 3.2 0.282
2PPBG, mmol/L 12.0 ± 3.5 14.4 ± 6.3 0.169
Hemoglubin, g/dL 13.5 ± 1.8 12.6 ± 1.8 0.059
Total cholesterol, mmol/L 4.7 ± 1.1 4.9 ± 1.8 0.469
HDL-C, mmol/L 1.3 ± 0.3 1.7 ± 1.7 0.526
Triglyceride, mmol/L 1.9 ± 1.0 1.9 ± 1.0 0.977
GGT, IU/L 26.6 ± 15.4 66.1 ± 51.6 0.000
AST, IU/L 23.4 ± 10.0 34.1 ± 22.7 0.022
ALT, IU/L 23.7 ± 13.4 29.9 ± 20.5 0.200
Urine ACR, µg/mg 1.5 ± 3.6 4.6 ± 8.4 0.004
BUN, mg/dL 18.4 ± 15.3 15.9 ± 7.3 0.420
Cr, mg/dL 1.1 ± 0.3 1.1 ± 0.5 0.303
CRP, mg/dL 0.9 ± 3.0 1.3 ± 3.9 0.036
DPP, diabetic peripheral polyneuropathy; FBG, fasting blood glu-
cose; 2PPBG, 2 hours postprandial blood glucose; HDL-C, high den-
sity lipoprotein cholesterol; GGT, gamma-glutamyl transferase; AST, 
aspartate aminotransferase; ALT,  alanine aminotransferase; ACR, al-
bumin-creatinine ratio; CRP, C-reactive protein.
Table 5. Odds ratios for association between key risk factors 
and the incidence of polyneuropathy using the logistic regres-
sion model
ORs 95% CI P value
Smoking 1.1 0.3 to 4.6 0.907
Retinopathy 3.6 0.6 to 23.5 0.173
SBP 1.0 0.9 to 1.1 0.612
DBP 1.1 0.9 to 1.2 0.392
GGT 1.1 1.0 to 1.1 0.001
AST 1.0 0.9 to 1.1 0.604
Urine ACR 1.1 0.9 to 1.3 0.416
CRP 0.9 0.8 to 1.1 0.481
ORs, odds ratios; CI, confidence interval; SBP, systolic blood pressure; 
DBP, diastolic blood pressure; GGT, gamma-glutamyl transferase; 
AST, aspartate aminotransferase; ACR, albumin-creatinine ratio; 
CRP, C-reactive protein.115
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DISCUSSION
Diabetic neuropathy is the most common complication of dia-
betes leading to foot ulcers or amputations in the future, which 
results in the rise in the socioeconomic burden owing to in-
creased morbidity and mortality [3]. Hence, early diagnosis of 
DPP may play an important role in the prevention and treat-
ment of foot ulcers. A number of methods have been applied 
for detection of DPP including the objective analysis of symp-
toms, neurologic physical examinations, and NCV studies. The 
most accurate diagnosis of DPP comprises a combination of 
clinical symptoms, signs, and several tests including NCV, not 
a single reference [14,15]. We conducted the MNSI for symp-
toms to detect peripheral polyneuropathy. A diagnosis of DPP 
required not only positive findings in NCV studies, but also sup-
portive evidence on neurological physical examinations. Par-
ticularly, we used the MNSI score as one of standard scale for 
symptoms of DPP because it has been reported that a cutoff of 
≥ 3 points in the continuous MNSI score was used as suggest-
ed diabetic polyneuropathy [5,12].
  Oxidative stress may contribute to the pathophysiology of 
the onset and progression of nerve injury in diabetic neuropa-
thy through defects in metabolic and vascular pathways [16]. 
Hyperglycemia increases the production of nicotinamide ade-
nine dinucleotide (NADH). This overproduction can lead to an 
overload of the electron transport chain causing oxidative stress, 
damage to mitochondria, and activation of poly (ADP-ribose) 
polymerase (PARP) [16]. This activation of PARP by reactive 
oxygen species (ROS) induces inflammation and neuronal dys-
function in conjunction with the hexosamine and protein ki-
nase C (PKC) pathways. The activation of advanced glycation 
endproducts (AGE), polyol, hexosamine, and PKC pathways 
with oxidative stress and hyperglycemia leads to redox imbal-
ance, gene expression disturbance, and further oxidative stress 
[16]. The inflammatory and neuronal dysfunction may occur 
through these pathways [17]. Therefore, systemic and neural 
oxidative stress produced in metabolic and vascular pathways 
may contribute to the onset and progression of diabetic neu-
ropathy [16]. Zotova et al. reported that single-nucleotide poly-
morphisms of the genes for mitochondrial and extracellular 
dismutases (SOD) may increase the risk for diabetic neuropa-
thy [18]. Alpha-lipoic acid, a powerful antioxidant, regenerates 
the glutathione that may prevent the spread of oxidative stress. 
Such treatment shows a significant improvement in nerve blood 
flow, NCV, regeneration capacity and protection of vascular 
endothelial function in DPP [19,20]. 
  It is very difficult to directly measure oxidative stress, and 
thus easy and inexpensive serum markers of oxidative stress 
are valuable. GGT has been known mainly as a marker of al-
cohol consumption or liver diseases, and serum GGT within 
normal ranges has been reported to be associated with risk 
factors of cardiovascular diseases and components of metabolic 
syndrome [21]. Although the relationship between celluar GGT 
and serum GGT is not clear, cellular GGT has been reported 
to be directly involved in the generation of ROS [22]. The in-
verse associations between antioxidants and serum GGT ac-
cording to venous sampling analysis have indicated the possi-
bility that serum GGT might be associated with oxidative stress 
[21,23]. Certain information supports this hypothesis. First, 
dietary heme iron has been used to positively predict the fu-
ture serum GGT concentration, although the portion of free 
iron causing oxidative stress was not measured. Second, most 
dietary antioxidants such as Vitamin C, and β-carotene have 
been reported to predict future serum GGT concentration, in 
an inverse relationship. Third, serum GGT has been used to 
predict CRP, a marker of inflammation, and F2-isoprostanes, a 
marker of oxidative damage due to arachidonic acid [21]. In 
addition, hypertension, diabetes, and hyperlipidemia, the ma-
jor risk factors of cardiovascular diseases, have been reported 
to be associated with oxidative stress in several recent studies 
[10,24,25]. In the present study, gender, postprandial blood 
glucose, and total cholesterol concentration were positively as-
sociated with serum GGT (Table 2). This information sup-
ports the supposition that serum GGT might be significant as 
a marker of oxidative stress. Therefore, we investigated wheth-
er serum GGT as a sensitive marker of oxidative stress which 
was considered to be part of pathophysiology of DPP might be 
significantly associated with the presence of polyneuropathy 
in type 2 diabetic patients. We found that serum GGT levels in 
patients with DPP were significantly higher than those in pa-
tients without polyneuropathy. Therefore we suggest that an 
increased level of serum GGT might have important clinical 
implications for the presence of DPP in patients with type 2 
diabetes. In addition, smoking, retinopathy, SBP, DBP, serum 
AST, CRP, and urinary ACR also showed significant associa-
tions as risk factors of DPP (P < 0.05, Tables 3 and 4). 
  Oxidative stress is one of the key factors in metabolic syn-
drome including insulin resistance, hypertension, obesity, and 
hyperlipidemia. In metabolic syndrome, the increase in ROS 116
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induces an increased oxidative stress with over-activation of 
NADPH oxidase and this process may reduce the bioavailabili-
ty of nitric oxide (NO), yielding low NO levels in patients with 
metabolic syndrome. Therefore, ROS or the increase in ROS is 
a key factor in metabolic syndrome, and oxidative stress is also 
associated with most components of metabolic syndrome [26]. 
Lim et al. [27] reported that serum GGT level within normal 
range might have an important clinical association with risk 
factors of cardiovascular diseases due to positive associations 
between serum GGT level and FBG, total cholesterol, triglyc-
eride, and uric acid levles. Koh et al. [28] reported that age, trig-
lyceride level, and waist circumference were important meta-
bolic syndrome components, and that ALT and GGT levels in 
particular might predict metabolic syndrome. In our study, 
GGT and AST were significantly increased in patients with 
DPP. In addition, other risk factors of DPP such as age, weight, 
gender, duration of DM, HbA1c, glucose levels, peripheral vas-
cular diseases, hypertension, cardiovascular diseases, and dys-
lipidemia have been reported [11,14,29,30]. In our study, age, 
gender, HbA1c, glucose levels, and lipid concentrations did not 
show significant associations with DPP. Particularly, smoking, 
hypertension, and lipid concentrations may be considered to 
be associated with peripheral polyneuropathy by blood flow 
impairment and aggravation of arteriosclerosis [11]. The cur-
rent study showed that smoking, retinopathy, SBP and DBP, 
not lipid profiles, were significantly associated with DPP. Hy-
poinsulinemia, decreased insulin secretory function of the pan-
creas as documented by C-peptide measurements, has been 
reported to be an additional risk factor for the development of 
diabetic polyneuropathy in type 2 diabetic patients [11]. How-
ever, our study showed no significanct association with insulin 
secretion. Recently, it has been reported that diabetic polyneu-
ropathy is associated with subclinical inflammation in partic-
ular with CRP, interleukin-6 (IL-6) and inversely, IL-18 [12]. 
CRP is an acute phase protein that is produced in the liver and 
induced by IL-6 mainly [12]. In our study, the CRP level mea-
sured in patients with DPP was significantly increased com-
pared with that of patients without DPP. Other studies on the 
pathophysiology  of DPP have been reported a decreased eryth-
ropoietin level in blood [31]. Additionally, an aldose reductase 
gene polymorphism [32] may play a role in the development 
of peripheral neuropathy in diabetic patients.
  In order to examine any independent associations between 
the presence of DPP and key risk factors, we performed a mul-
tiple logistic regression analysis with the significant eight vari-
ables from univariate analysis. These eight factors were smok-
ing, retinopathy, SBP, DBP, serum GGT, AST, CRP and urine 
ACR. It was found that only serum GGT remained significant-
ly associated with the presence of DPP. This association was 
independent and carried an odds ratio of 1.1 (P < 0.01, Table 5).
  There were some limitations in this study. First, only medi-
cal history and a questionnaire were used to evaluate cardio-
vascular events or autonomic neuropathy. The lack of clinical 
evaluations to detect or diagnose latent cardiovascular or au-
tonomic complications may have caused an under-reported 
incidence. Recent studies have reported that cardiovascular 
risk factors may predict the development of large-fiber dysfunc-
tion in patients with DPP [29]. There may be a significant rela-
tionship between DPP and cardiovascular autonomic neurop-
athy [33]. Therefore, additional studies are necessary to evalu-
ate this relationship. Second, strict and accurate guidelines for 
several tests and neurological examinations may also be neces-
sary to avoid misleading results owing to subjective tendencies 
or technical variations. Third, diabetic nephropathy is usually 
defined by the presence of proteinuria > 0.5 g/24 hour or two 
out of three samples spot-collected over a 3-to 6-month period 
for ACR [13]. However, we investigated ACR only once on ad-
mission. Finally, there is a limit to explain the cause and patho-
genesis of DPP with only oxidative stress except other factors.
Future prospective long-term studies are necessary to evaluate 
the clinical relationship between GGT and DPP and a patho-
genesis of DPP in a larger population. 
  In summary, this study indicates that increased levels of se-
rum GGT may be significantly related to the presence of DPP 
in patients with type 2 DM. Additional studies are necessary 
to confirm these hypotheses to treat and prevent DPP in a larg-
er population.
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